Endo T, Sawada K, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T
Department of Internal Medicine II, Hokkaido University School of Medicine.
Rinsho Ketsueki. 2000 Apr;41(4):322-8.
Hepatitis B virus (HBV) reactivation in patients with positive hepatitis B surface antibody (HBsAb) has been reported in some cases of allogenic bone marrow transplantation, acquired immunodeficiency syndrome (AIDS), and organ transplantation. However, to our knowledge, no reports have been made on the frequency and risk factors involved in HBV reactivation after autologous peripheral blood stem cell transplantation (APBSCT). Forty seven patients who underwent APBSCT were retrospectively analyzed. Three patients who were HBsAb positive before APBSCT contracted post-transplant HBV acute hepatitis. All 3 patients had multiple myeloma. HBV DNA could not be demonstrated in preserved samples of transfused blood. Therefore, we speculated that reactivation of latent HBV had occurred. The 3 patients with HBV hepatitis had relatively lower titers of pre-transplant HBsAb, and the total dose of steroids they received after APBSCT was significantly higher than for other patients who did not experience post-transplant HBV reactivation. There were no significant differences in pre-transplant hepatitis B core antibody (HBcAb) titer or total post-transplant blood transfusion volume. Our study suggested that immunocompromised states, especially those induced by high-dose steroid therapy, may allow the reactivation of HBV after APBSCT, even in patients who had HBsAb before APBSCT.
在同种异体骨髓移植、获得性免疫缺陷综合征(AIDS)及器官移植的部分病例中,曾有报告称乙肝表面抗体(HBsAb)阳性患者出现乙型肝炎病毒(HBV)再激活。然而,据我们所知,尚无关于自体外周血干细胞移植(APBSCT)后HBV再激活的发生率及危险因素的报道。我们对47例行APBSCT的患者进行了回顾性分析。3例在APBSCT前HBsAb阳性的患者发生了移植后HBV急性肝炎。所有3例患者均患有多发性骨髓瘤。在输注血液的留存样本中未检测到HBV DNA。因此,我们推测发生了潜伏HBV的再激活。3例HBV肝炎患者移植前HBsAb滴度相对较低,且他们在APBSCT后接受的类固醇总剂量显著高于其他未发生移植后HBV再激活的患者。移植前乙肝核心抗体(HBcAb)滴度或移植后输血总量无显著差异。我们的研究表明,免疫功能低下状态,尤其是由高剂量类固醇治疗引起的免疫功能低下状态,可能会使APBSCT后的患者出现HBV再激活,即使是那些在APBSCT前已有HBsAb的患者。